{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:21:46Z","timestamp":1792790506897,"version":"4.5.0"},"reference-count":36,"publisher":"PeerJ","license":[{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune disorders and autoantibodies has been noted in both primary immune thrombocytopenia (ITP) and systemic lupus erythematosus (SLE). Whether the two disorders are correlated is unclear. The lack of evidence on the incidence of and risk factors for SLE in primary ITP patients poses a challenge for prediction in clinical practice. Therefore, we conducted this study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The protocol was registered with PROSPERO (CRD42023403665). Web of Science, Cochrane, PubMed, and EMBASE were searched for articles published from inception to 30 September 2023 on patients who were first diagnosed with primary ITP and subsequently developed into SLE. Furthermore, the risk factors were analyzed. Study quality was estimated using the Newcastle-Ottawa Scale. The statistical process was implemented using the R language.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This systematic review included eight articles. The incidence of SLE during the follow-up after ITP diagnosis was 2.7% (95% CI [1.3\u20134.4%]), with an incidence of 4.6% (95% CI [1.6\u20138.6%]) in females and 0 (95% CI [0.00\u20130.4%]) in males. Older age (OR = 6.31; 95% CI [1.11\u201334.91]), positive antinuclear antibody (ANA) (OR = 6.64; 95% CI [1.40\u201331.50]), hypocomplementemia (OR = 8.33; 95% CI [1.62\u201342.91]), chronic ITP (OR = 24.67; 95% CI [3.14\u2013100.00]), organ bleeding (OR = 13.67; 95% CI [2.44\u201376.69]), and female (OR = 20.50; 95% CI [4.94\u201384.90]) were risk factors for subsequent SLE in ITP patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with primary ITP are at higher risk of SLE. Specific follow-up and prevention strategies should be tailored especially for older females with positive ANA, hypocomplementemia, or chronic ITP. In subsequent studies, we need to further investigate the risk factors and try to construct corresponding risk prediction models to develop specific prediction strategies for SLE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.7717\/peerj.17152","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T03:55:22Z","timestamp":1713758122000},"page":"e17152","source":"Crossref","is-referenced-by-count":6,"title":["Incidence and risk factors of systemic lupus erythematosus in patients with primary immune thrombocytopenia: a systematic review and meta-analysis"],"prefix":"10.7717","volume":"12","author":[{"given":"En-min","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8683-7842","authenticated-orcid":true,"given":"Heping","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4443","published-online":{"date-parts":[[2024,4,22]]},"reference":[{"issue":"5","key":"10.7717\/peerj.17152\/ref-1","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2169\/internalmedicine1962.29.481","article-title":"Thrombocytopenia subsequently develops systemic lupus erythematosus--can anti-SS-A antibody predict the next event?","volume":"29","author":"Adachi","year":"1990","journal-title":"Japanese Journal of Medicine"},{"issue":"1","key":"10.7717\/peerj.17152\/ref-2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s13075-022-02901-y","article-title":"Prognostic factors for the development of systemic lupus erythematosus in patients with immune thrombocytopenia","volume":"24","author":"Ahn","year":"2022","journal-title":"Arthritis Research & Therapy"},{"issue":"2","key":"10.7717\/peerj.17152\/ref-3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s11239-007-0031-y","article-title":"Prevalence and clinical significance of elevated antinuclear antibody test in children and adult patients with idiopathic thrombocytopenic purpura","volume":"24","author":"Altintas","year":"2007","journal-title":"Journal of Thrombosis and Thrombolysis"},{"issue":"3","key":"10.7717\/peerj.17152\/ref-4","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/j.semarthrit.2019.09.009","article-title":"EULAR\/ACR classification criteria for SLE","volume":"49","author":"Aringer","year":"2019","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"6","key":"10.7717\/peerj.17152\/ref-5","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.autrev.2017.04.012","article-title":"Pathogenesis of immune thrombocytopenia","volume":"16","author":"Audia","year":"2017","journal-title":"Autoimmunity Reviews"},{"issue":"5","key":"10.7717\/peerj.17152\/ref-6","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/rth2.12388","article-title":"Serum complement levels in immune thrombocytopenia: characterization and relation to clinical features","volume":"4","author":"Cheloff","year":"2020","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"key":"10.7717\/peerj.17152\/ref-7","doi-asserted-by":"publisher","first-page":"654791","DOI":"10.3389\/fmed.2021.654791","article-title":"Risk of systemic lupus erythematosus in patients with anti-phospholipid syndrome: a population-based study","volume":"8","author":"Chen","year":"2021","journal-title":"Frontiers in Medicine (Lausanne)"},{"issue":"10","key":"10.7717\/peerj.17152\/ref-8","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1056\/NEJMcp1810479","article-title":"Immune thrombocytopenia","volume":"381","author":"Cooper","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"10.7717\/peerj.17152\/ref-9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.imlet.2016.12.002","article-title":"Gender differences of B cell signature related to estrogen-induced IFI44L\/BAFF in systemic lupus erythematosus","volume":"181","author":"Fan","year":"2017","journal-title":"Immunology Letters"},{"issue":"6","key":"10.7717\/peerj.17152\/ref-10","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1136\/annrheumdis-2020-217356","article-title":"Population-based studies in systemic lupus erythematosus: immune thrombocytopenic purpura or \u2018blood-dominant\u2019 lupus?","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.7717\/peerj.17152\/ref-11","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/ped4.12309","article-title":"The role of epigenetics in childhood autoimmune diseases with hematological manifestations","volume":"6","author":"Gkoutsias","year":"2022","journal-title":"Pediatric Investigation"},{"issue":"2","key":"10.7717\/peerj.17152\/ref-12","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1136\/annrheumdis-2019-215782","article-title":"Transcriptome reprogramming and myeloid skewing in haematopoietic stem and progenitor cells in systemic lupus erythematosus","volume":"79","author":"Grigoriou","year":"2020","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.7717\/peerj.17152\/ref-13","doi-asserted-by":"publisher","first-page":"e24447","DOI":"10.7759\/cureus.24447","article-title":"Immune thrombocytopenic purpura and intracerebral hemorrhage, incidence, and mortality","volume":"14","author":"Hallan","year":"2022","journal-title":"Cureus"},{"key":"10.7717\/peerj.17152\/ref-14","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/(ISSN)1545-5017","article-title":"Risk factors for future development of systemic lupus erythematosus in children with idiopathic thrombocytopenic purpura","volume":"47","author":"Hazzan","year":"2006","journal-title":"Pediatric Blood & Cancer"},{"issue":"9","key":"10.7717\/peerj.17152\/ref-15","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis and Rheumatism"},{"issue":"12","key":"10.7717\/peerj.17152\/ref-16","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s002770000219","article-title":"Intracranial hemorrhage in children with immune thrombocytopenic purpura","volume":"79","author":"Iyori","year":"2000","journal-title":"Annals of Hematology"},{"issue":"01","key":"10.7717\/peerj.17152\/ref-17","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1160\/TH12-07-0468","article-title":"Differential expression of T-cell genes in blood and bone marrow between ITP patients and controls","volume":"109","author":"Jern\u00e5s","year":"2013","journal-title":"Thrombosis and Haemostasis"},{"issue":"8","key":"10.7717\/peerj.17152\/ref-18","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1111\/ced.13688","article-title":"Idiopathic thrombocytopenic purpura in a patient with IgG4-related disease","volume":"43","author":"Jimura","year":"2018","journal-title":"Clinical and Experimental Dermatology"},{"issue":"7","key":"10.7717\/peerj.17152\/ref-19","doi-asserted-by":"publisher","first-page":"e606","DOI":"10.1097\/MPH.0000000000001836","article-title":"Latent and overt polyautoimmunity in children and adolescents with immune thrombocytopenia","volume":"42","author":"Kamioka","year":"2020","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"issue":"8","key":"10.7717\/peerj.17152\/ref-20","doi-asserted-by":"publisher","first-page":"e29146","DOI":"10.1002\/pbc.29146","article-title":"Childhood-onset systemic lupus erythematosus and immune thrombocytopenia: prevalence and risk factors","volume":"68","author":"Kittivisuit","year":"2021","journal-title":"Pediatric Blood & Cancer"},{"issue":"03","key":"10.7717\/peerj.17152\/ref-21","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1055\/s-0039-1683416","article-title":"Epidemiology and clinical manifestations of immune thrombocytopenia","volume":"39","author":"Kohli","year":"2019","journal-title":"Hamostaseologie"},{"issue":"21","key":"10.7717\/peerj.17152\/ref-22","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1182\/blood-2017-03-754119","article-title":"Clinical updates in adult immune thrombocytopenia","volume":"129","author":"Lambert","year":"2017","journal-title":"Blood"},{"issue":"7","key":"10.7717\/peerj.17152\/ref-23","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1177\/0961203315624557","article-title":"Association between interferon-\u03b3 +874 T\/A polymorphism and susceptibility to autoimmune diseases: a meta-analysis","volume":"25","author":"Lee","year":"2016","journal-title":"Lupus"},{"issue":"1","key":"10.7717\/peerj.17152\/ref-24","doi-asserted-by":"publisher","first-page":"e000523","DOI":"10.1136\/lupus-2021-000523","article-title":"ANA-positive primary immune thrombocytopaenia: a different clinical entity with increased risk of connective tissue diseases","volume":"8","author":"Liu","year":"2021","journal-title":"Lupus Science & Medicine"},{"issue":"9","key":"10.7717\/peerj.17152\/ref-25","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1182\/blood-2009-05-223305","article-title":"Antinuclear antibody (ANA)-positive thrombocytopenia: primary, but with a difference","volume":"114","author":"Marmont","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.7717\/peerj.17152\/ref-26","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1182\/bloodadvances.2020001664","article-title":"Significance of antinuclear antibodies in primary immune thrombocytopenia: results of the CARMEN registry","volume":"4","author":"Moulis","year":"2020","journal-title":"Blood Advances"},{"issue":"2","key":"10.7717\/peerj.17152\/ref-27","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1600-0609.2011.01718.x","article-title":"Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP)","volume":"88","author":"Najaoui","year":"2012","journal-title":"European Journal of Haematology"},{"issue":"23","key":"10.7717\/peerj.17152\/ref-28","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American society of hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Advances"},{"issue":"4","key":"10.7717\/peerj.17152\/ref-29","doi-asserted-by":"publisher","first-page":"103297","DOI":"10.1016\/j.autrev.2023.103297","article-title":"Development of systemic lupus erythematosus in patients with immune thrombocytopenic purpura: a systematic meta-analysis","volume":"22","author":"Pamuk","year":"2023","journal-title":"Autoimmunity Reviews"},{"issue":"8","key":"10.7717\/peerj.17152\/ref-30","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/s00277-002-0488-x","article-title":"Overview of 321 patients with idiopathic thrombocytopenic purpura. Retrospective analysis of the clinical features and response to therapy","volume":"81","author":"Pamuk","year":"2002","journal-title":"Annals of Hematology"},{"issue":"2","key":"10.7717\/peerj.17152\/ref-31","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/apa.15593","article-title":"Primary immunodeficiencies, autoimmune hyperthyroidism, coeliac disease and systemic lupus erythematosus in childhood immune thrombocytopenia","volume":"110","author":"Saettini","year":"2021","journal-title":"Acta Paediatrica"},{"issue":"3","key":"10.7717\/peerj.17152\/ref-32","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1080\/09537104.2019.1635687","article-title":"The incidence and clinical burden of immune thrombocytopenia in pediatric patients in the United States","volume":"31","author":"Shaw","year":"2020","journal-title":"Platelets"},{"issue":"7","key":"10.7717\/peerj.17152\/ref-33","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s00277-022-04836-5","article-title":"Potential risk factors for the development from immune thrombocytopenia to systemic lupus erythematosus: a case-control study in Chinese children","volume":"101","author":"Song","year":"2022","journal-title":"Annals of Hematology"},{"issue":"3","key":"10.7717\/peerj.17152\/ref-34","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jaut.2006.09.001","article-title":"Autoantibody profiling to identify individuals at risk for systemic lupus erythematosus","volume":"27","author":"Wandstrat","year":"2006","journal-title":"Journal of Autoimmunity"},{"issue":"3","key":"10.7717\/peerj.17152\/ref-35","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11926-021-00984-1","article-title":"A review of complement activation in SLE","volume":"23","author":"Weinstein","year":"2021","journal-title":"Current Rheumatology Reports"},{"issue":"6","key":"10.7717\/peerj.17152\/ref-36","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1136\/annrheumdis-2020-217013","article-title":"Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: a population-based cohort study","volume":"79","author":"Zhu","year":"2020","journal-title":"Annals of the Rheumatic Diseases"}],"container-title":["PeerJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/peerj.com\/articles\/17152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/17152.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/17152.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/17152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T03:55:31Z","timestamp":1713758131000},"score":1,"resource":{"primary":{"URL":"https:\/\/peerj.com\/articles\/17152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,22]]},"references-count":36,"alternative-id":["10.7717\/peerj.17152"],"URL":"https:\/\/doi.org\/10.7717\/peerj.17152","archive":["CLOCKSS","LOCKSS","Portico"],"relation":{},"ISSN":["2167-8359"],"issn-type":[{"value":"2167-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,22]]},"article-number":"e17152"}}